<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00629616</url>
  </required_header>
  <id_info>
    <org_study_id>CARMINA02</org_study_id>
    <secondary_id>CARMINA-02/0609</secondary_id>
    <secondary_id>2006-006409-10</secondary_id>
    <secondary_id>NIMFEA</secondary_id>
    <nct_id>NCT00629616</nct_id>
  </id_info>
  <brief_title>Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer</brief_title>
  <acronym>NIMFEA</acronym>
  <official_title>A Randomized Multicenter Phase II Study Identifying Hormone Sensitivity Profiles and Evaluating the Efficacy of Anastrozole and Fulvestrant in the Neo-adjuvant Treatment of Operable Breast Cancer in Postmenopausal Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using&#xD;
      anastrozole or fulvestrant may fight breast cancer by lowering the amount of estrogen the&#xD;
      body makes or by blocking the use of estrogen by the tumor cells. Giving hormone therapy&#xD;
      before surgery may be an effective treatment for breast cancer. It is not yet known whether&#xD;
      anastrozole is more effective than fulvestrant when given before surgery in treating women&#xD;
      with breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying anastrozole to see how well it works&#xD;
      compared with fulvestrant in treating postmenopausal women with stage II or stage III breast&#xD;
      cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare the clinical response rates (complete and partial responses) at 6 months in&#xD;
           postmenopausal women with operable stage II or III breast cancer treated with&#xD;
           neoadjuvant anastrozole vs fulvestrant.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare the breast surgery conservation rate in patients treated with these drugs.&#xD;
&#xD;
        -  To correlate imaging findings by mammography, ultrasonography, and MRI with histological&#xD;
           and clinical response in these patients and with sensitivity profile to these drugs.&#xD;
&#xD;
        -  To compare histological response in patients treated with these drugs.&#xD;
&#xD;
        -  To define criteria appropriate for neoadjuvant hormonal therapy.&#xD;
&#xD;
        -  To correlate baseline molecular characteristics and modifications during treatment with&#xD;
           response in these patients.&#xD;
&#xD;
        -  To compare the tolerability of these drugs in these patients.&#xD;
&#xD;
        -  To compare the serum proteomic profile of patients treated with these drugs.&#xD;
&#xD;
        -  To correlate 3-year event-free and overall survival rates with clinical and histological&#xD;
           response in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral anastrozole once daily for 4-6 months in the absence of&#xD;
           clinical progression.&#xD;
&#xD;
        -  Arm II: Patients receive fulvestrant intramuscularly on days 1, 15, and 29 in the first&#xD;
           month and then every 28 days in each subsequent month. Treatment continues for 4-6&#xD;
           months in the absence of clinical progression.&#xD;
&#xD;
      Patients in both arms then undergo surgery and radiotherapy according to institutional&#xD;
      guidelines. Patients then receive adjuvant hormonal therapy for at least 5 years.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2007</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical tumor response as assessed by RECIST criteria</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast surgery conservation rate</measure>
    <time_frame>Post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological tumor response as assessed by the Sataloff scale</measure>
    <time_frame>Post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response as assessed by mammography, ultrasonography (RECIST criteria), and MRI</measure>
    <time_frame>at baseline, after the first month of treatment, and then before surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological prognosis and predictive response factors</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by NCI CTCAE v3.0</measure>
    <time_frame>During neoadjuvant treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anastrozole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>1 mg/day for either 4 months or 6 months depending on the clinical evaluation</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <description>500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed infiltrating breast adenocarcinoma&#xD;
&#xD;
               -  Large, operable tumor&#xD;
&#xD;
               -  Stage T2 (≥ 3 cm) or T3-T4 (excluding inflammatory disease), N0-N3, M0 disease&#xD;
&#xD;
                    -  No bilateral inflammatory breast tumors (T4d [PEV-2 or PEV-3])&#xD;
&#xD;
               -  Elston-Ellis grade I or II and mitotic index 1 or 2 (if &lt; 65 years of age)&#xD;
&#xD;
          -  At least 1 embedded and 1 frozen biopsy sample available&#xD;
&#xD;
          -  No multifocal or multicentric tumors for which breast conservation cannot be envisaged&#xD;
&#xD;
          -  No ErbB2-overexpressing tumors (HER2 3+ by IHC OR HER2 2+ by IHC and FISH positive)&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor and/or progesterone receptor positive tumor (&gt; 10%) as assessed&#xD;
                  by IHC&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 2,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 1.25 times ULN&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  No other cancer within the past 10 years, except basal cell skin cancer or previously&#xD;
             treated carcinoma in situ of the cervix&#xD;
&#xD;
          -  No uncontrolled cardiac pathology, including any of the following:&#xD;
&#xD;
               -  Angina pectoris&#xD;
&#xD;
               -  Congestive cardiac insufficiency&#xD;
&#xD;
               -  Myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No known history of hemorrhagic diathesis&#xD;
&#xD;
          -  No known allergy to the study drugs or their excipients&#xD;
&#xD;
          -  No congenital galactosemia, glucose malabsorption syndrome, or lactase deficiency&#xD;
&#xD;
          -  No chronic somatic or psychiatric illness with pejorative prognosis&#xD;
&#xD;
          -  No geographical, social, or psychiatric condition that would preclude study compliance&#xD;
             and follow-up schedule&#xD;
&#xD;
          -  No individual deprived of liberty or placed under the authority of a tutor&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy, hormonal therapy, or any targeted treatment for the breast&#xD;
             tumor&#xD;
&#xD;
          -  At least 2 weeks since prior hormone replacement therapy for menopause&#xD;
&#xD;
          -  No concurrent long-term anticoagulation treatment&#xD;
&#xD;
          -  No concurrent participation on another therapeutic trial involving an experimental&#xD;
             molecule&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence Lerebours, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Dupuytren</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/27315583/</url>
    <description>Cancer . 2016 Oct;122(19):3032-40. doi: 10.1002/cncr.30143. Epub 2016 Jun 17.</description>
  </link>
  <results_reference>
    <citation>Lerebours F, Rivera S, Mouret-Reynier MA, Alran S, Venat-Bouvet L, Kerbrat P, Salmon R, Becette V, Bourgier C, Cherel P, Boussion V, Balleyguier C, Thibault F, Lavau-Denes S, Nabholz JM, Sigal B, Trassard M, Mathieu MC, Martin AL, Lemonnier J, Mouret-Fourme E. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609). Cancer. 2016 Oct;122(19):3032-40. doi: 10.1002/cncr.30143. Epub 2016 Jun 17.</citation>
    <PMID>27315583</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2008</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

